Ocugen Inc. to Present at Upcoming March Investor Conferences

March 8, 2021 at 2:51 PM EST

MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference being held on March 9-10, the 33rd Annual Roth Conference being held on March 15-17, and the Oppenheimer 31st Annual Healthcare Conference being held on March 16-18.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate virtually at all three conferences. At HC Wainwright, he will participate in a fireside chat. At Roth he will participate in a COVID panel, and at Oppenheimer he will discuss the development of Ocugen’s breakthrough modifier gene therapy, its novel biologic product candidate, and COVID-19 vaccine candidate, COVAXIN™ for the US market.

Presentation Details:

Conference: H.C. Wainwright Global Life Sciences Conference
Format: Fireside Chat
Date: Tuesday, March 9 – Wednesday, March 10, 2021
Time: On demand beginning on March 9 at 7 a.m. EST
Registration Link: https://journey.ct.events/view/ffe8580d-06ea-47a5-8bb8-c9bd92e65388

Conference: 33rd Annual Roth Conference
Format: Panel Entitled “Therapies and Vaccines In the Fight Against COVID-19”
Date: Monday, March 15, 2021
Time: 3 p.m. EST
Conference Link: https://wsw.com/webcast/roth35/panel5/2041785

Conference: Oppenheimer 31st Annual Healthcare Conference
Format: Company Presentation
Date: Tuesday, March 16, 2021
Time: 11:20 a.m. - 11:50 a.m. EST
Conference Link: https://wsw.com/webcast/oppenheimer9/ocgn/2703987

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data that is the subject of this release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN; whether and when any such applications may be approved by the FDA; decisions by the FDA impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development

Media Contact:
Emmie Twombly
+1 857-389-6042